Imunologia Pediátrica

Tratamento anti-inflamatório da doença de Kawasaki: comparação das atuais diretrizes e perspectivas.

25 Fev, 2022 | 13:59h

Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives – Frontiers in Medicine

Diretriz ACR para síndrome inflamatória multissistêmica em crianças associada com infecção pelo SARS-CoV-2 e hiperinflamação na COVID-19 pediátrica.

15 Fev, 2022 | 11:51h

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3 – Arthritis & Rheumatism

Comentário e resumo: ACR Updates Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With COVID – RheumNow

Diretriz de prática clínica para uso de tubos de timpanostomia em crianças.

10 Fev, 2022 | 13:58h

Executive Summary of Clinical Practice Guideline on Tympanostomy Tubes in Children (Update) – Otolaryngology–Head and Neck Surgery

Breve revisão | Reações de hipersensibilidade a vacinas em crianças: do sarampo ao SARS-CoV-2.

4 Fev, 2022 | 15:34h

Hypersensitivity reactions to vaccines in children: from measles to SARS-CoV-2 – Pediatric Allergy and Immunology

Comentário: Vaccine hypersensitivity in children – News Medical

Estudo randomizado | Em crianças alérgicas a amendoim, imunoterapia oral antes dos 4 anos de idade induziu dessensibilização em 71% dos pacientes e remissão em 21%.

25 Jan, 2022 | 11:47h

Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study – The Lancet (link para o resumo – $ para o texto completo)

Comunicado de imprensa: Oral immunotherapy induces remission of peanut allergy in some young children – NIH News Releases

Comentário: Peanut Oral Immunotherapy at Younger Age Ups Desensitization in Children – HealthDay

Em um estudo com 1.110 crianças com febre prolongada, os níveis sorológicos de MRP8/14 foram validados como marcador diagnóstico para artrite idiopática juvenil sistêmica.

17 Jan, 2022 | 12:53h

MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever – Rheumatology (link para o resumo – $ para o texto completo)

Comentário: It is about time: the first validated biomarker for early diagnosis of sJIA – Rheumatology

Estudo randomizado | Em crianças de 6 a 11 anos com asma moderada a grave sem controle adequado, a adição de dupilumabe reduziu as exacerbações e melhorou a função pulmonar.

9 Dez, 2021 | 15:28h

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma – New England Journal of Medicine

Comentário: International study supports dupilumab for treatment of moderate-to-severe asthma in children – Vanderbilt University Medical Center

Relatório Clínico AAP | Biológicos para asma e doenças alérgicas cutâneas em crianças.

19 Nov, 2021 | 13:03h

Biologics for Asthma and Allergic Skin Diseases in Children – Pediatrics

Atualização sobre a síndrome inflamatória multissistêmica em crianças relacionada ao SARS-CoV-2.

11 Nov, 2021 | 16:17h

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2 – The Pediatric Infectious Diseases Journal

Conteúdos relacionados:

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Dez coisas a saber sobre a síndrome inflamatória multissistêmica em crianças (multisystem inflammatory syndrome in children – MIS-C).

4 Nov, 2021 | 12:01h

Ten Things to Know About MIS-C – American College of Cardiology